Courtney Marabella

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

Faith E. Davies, MD, discusses the how to approach patients with high-risk myeloma, as well as how isatuximab and CAR T-cell therapies fit best for that patient population.

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

Bijal Shah, MD, MS, discusses the key findings of the ZUMA-3 trial, as well as key safety information regarding brexucabtagene autoleucel as a treatment for patients with heavily pretreated patients with relapsed/refractory B-cell ALL.

In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

The addition of olaparib to bevacizumab provided a substantial progression-free survival (PFS) and second PFS benefit over bevacizumab alone in the maintenance treatment of patients with homologous recombination deficiency–positive, newly diagnosed advanced ovarian cancer, regardless of International Federation of Gynecology and Obstetrics disease stage.

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.

TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.

A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence.

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

The integration of the anti-CD30 antibody-drug conjugate brentuximab vedotin into the frontline treatment of pediatric patients with high-risk Hodgkin lymphoma resulted in favorable clinical outcomes with promising tolerability and a reduction in radiation exposure, according to data from a phase 2 HLHR130 trial.

The PARP inhibitor rucaparib has proven to be a safe and effective maintenance option for patients with platinum-sensitive, advanced pancreatic cancer that harbors pathogenic variants such as BRCA1, BRCA2, or PALB2.

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Prophylactic whole-pelvic radiotherapy improved biochemical failure-free survival and disease-free survival vs prostate-only radiotherapy in patients with high-risk, locally advanced prostate cancer.

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.

Jose Pacheco, MD, discusses key agents that have significantly improved the care of patients with NSCLC harboring RET or NTRK fusions and efforts being made to address resistance challenges.

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

Novel combinations are paramount for patients with relapsed/refractory multiple myeloma who are in second relapse or beyond; some isatuximab-irfc–containing regimens have the potential to move to the frontline setting and combining melphalan flufenamide with proteasome inhibitors and anti-CD38 monoclonal antibodies is an active area of interest.

One in 6 patients with colorectal cancer harbor genetic changes that substantially increase their risk for cancer, especially in those who are younger at the time of diagnosis.

Three months of adjuvant capecitabine plus oxaliplatin represents a potential option for select patients with high-risk stage II colorectal cancer due to its convenience, reduced toxicity, and cost, although noninferiority to the 6-month standard duration was not demonstrated.

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC